公开(公告)号：WO2019006022A1

公开(公告)日：2019-01-03

申请号：PCT/US2018/039843

申请日：2018-06-27

Applicant: THE BROAD INSTITUTE, INC. ,  THE GENERAL HOSPITAL CORPORATION ,  XAVIER, Ramnik

Inventor： XAVIER, Ramnik ,  GRAHAM, Daniel B. ,  LUO, Chengwei

IPC: G06F19/22 ,  A61K39/00 ,  A61K39/02 ,  A61K38/10 ,  A61K35/15 ,  C07K7/08

CPC classification number: A61K39/02 ,  A61K2039/57 ,  A61K2039/605 ,  A61P31/04 ,  C07K14/195 ,  G01N33/68 ,  G01N2333/52 ,  G01N2333/5428 ,  G01N2333/545 ,  G01N2333/57 ,  G01N2800/24 ,  G06N3/0454 ,  G06N3/084

Abstract: A system and method for prediction of immunodominant epitopes is provided herein. MHCII peptidomics was used to discover complex bacterial epitopes and host antigen processing pathways. Novel insights into the features of antigenicity are leveraged to build an algorithm for prediction of immunodominant epitopes. Use of immunodominant epitopes is described.

公开(公告)号：WO2017095324A1

公开(公告)日：2017-06-08

申请号：PCT/SG2016/050441

申请日：2016-09-09

Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH ,  TESSA THERAPEUTICS PTE. LTD. ,  SINGAPORE HEALTH SERVICES PTE. LTD.

Inventor： CONNOLLY, John ,  HOPKINS, Richard ,  TOH, Han Chong

IPC: C12Q1/68 ,  G01N33/574 ,  A61K35/17 ,  A61P35/00

CPC classification number: A61K39/245 ,  A61K35/17 ,  A61K2039/5158 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C12N7/00 ,  C12N2710/16234 ,  C12N2710/16271 ,  C12Q1/68 ,  C12Q1/6886 ,  C12Q1/701 ,  C12Q1/705 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57407 ,  G01N33/57423 ,  G01N33/57438 ,  G01N33/57446 ,  G01N2333/05 ,  G01N2333/521 ,  G01N2333/57 ,  G01N2800/52

Abstract: A method for predicting whether a patient will be a long-term survivor on treatment of a disease by adoptive cell transfer (ACT), is disclosed comprising: (i) analysing a blood-derived sample obtained from the patient for one or more prognostic markers of long-term survival on treatment of a disease by ACT, and; (ii) based on the analysis of step (i), predicting whether the patient will be a long-term survivor on treatment of the disease by ACT, wherein the disease is preferably a disease caused or exacerbated by infection with Epstein-Barr virus (EBV), such as EBV-positive nasopharyngeal carcinoma (NPC). Also disclosed are methods for treating a patient by ACT, methods for selecting a patient for treatment by ACT, and methods for selecting a patient for treatment of a disease by ACT, preferably EBV-positive NPC.

Abstract translation: 公开了一种用于预测患者是否将成为通过过继性细胞转移（ACT）治疗疾病的长期存活者的方法，其包括：（i）分析从以下获得的血液来源的样品： 所述患者针对ACT治疗疾病的长期存活的一个或多个预后标记物，以及; （ii）基于步骤（i）的分析，预测患者是否是ACT治疗该疾病的长期存活者，其中该疾病优选是由Epstein-Barr病毒感染引起或加剧的疾病（ EBV），如EBV阳性鼻咽癌（NPC）。 还公开了通过ACT治疗患者的方法，选择ACT治疗患者的方法以及选择ACT治疗疾病的患者，优选EBV阳性NPC的方法。

公开(公告)号：WO2016106160A1

公开(公告)日：2016-06-30

申请号：PCT/US2015/066955

申请日：2015-12-19

Applicant: ENUMERAL BIOMEDICAL HOLDINGS, INC.

Inventor： TINKELENBERG, Arthur, H. ,  NGUYEN, Anhco ,  CHIU, Maria, Isabel ,  JONCA, Aleksander ,  MCQUADE, Thomas ,  VADDE, Sri, Sahitya ,  RANGANATH, Sheila

IPC: G01N33/50 ,  G01N33/68

CPC classification number: G01N33/5023 ,  G01N33/5047 ,  G01N33/6854 ,  G01N2333/52 ,  G01N2333/535 ,  G01N2333/54 ,  G01N2333/57 ,  G01N2333/70514 ,  G01N2333/70517 ,  G01N2333/70596

Abstract: Methods of selecting test compounds on the basis of their cellular response profiles are disclosed. For a given test compound, a cellular response is determined by introducing into an array of individually addressable microwells a population of cells comprising a plurality of cell types and contacting the cells with the test compound. The cellular response profile for the test compound is then compared to a desired cellular response profile, and the test compound is selected based on the comparison.

Abstract translation: 公开了根据其细胞反应特征选择测试化合物的方法。 对于给定的测试化合物，通过将包含多种细胞类型并将细胞与测试化合物接触的细胞群体引入单独可寻址的微孔阵列来确定细胞应答。 然后将测试化合物的细胞反应特征与期望的细胞反应谱比较，并且基于比较选择测试化合物。

公开(公告)号：WO2016030526A1

公开(公告)日：2016-03-03

申请号：PCT/EP2015/069791

申请日：2015-08-28

Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S) ,  CONICET (CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS) ,  INSTITUT JEAN PAOLI & IRENE CALMETTES ,  UNIVERSITÉ D'AIX-MARSEILLE ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

Inventor： IOVANNA, Juan ,  PASQUINELLI, Virginia ,  GHERARDI, Maria Madgalena ,  CHULUYAN, Hector Eduardo ,  ROVETTA, Ana Inès ,  PENA, Delfina ,  GARCIA, Véronica Edith

IPC: G01N33/569

CPC classification number: G01N33/6893 ,  C07K14/35 ,  C12N5/0634 ,  G01N33/5695 ,  G01N2333/35 ,  G01N2333/57

Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.

Abstract translation: 本发明涉及包含至少三种衍生自结核分枝杆菌抗原Rv2626c的肽的组合物，其用于潜伏感染的结核分枝杆菌（LTBI）受试者的诊断，相应的使用方法和试剂盒。

公开(公告)号：WO2015164722A1

公开(公告)日：2015-10-29

申请号：PCT/US2015/027489

申请日：2015-04-24

Applicant: IMMUSANT, INC.

Inventor： ANDERSON, Robert, P. ,  TYE-DIN, Jason, A.

IPC: A23J1/00 ,  A23J3/14 ,  A21D13/04 ,  A21D13/06 ,  A21D13/08 ,  A61K38/02 ,  A61P1/00

CPC classification number: A61K39/0008 ,  A61K38/168 ,  A61K2039/55 ,  A61K2039/577 ,  C07K7/06 ,  C07K7/08 ,  C07K14/55 ,  G01N33/5091 ,  G01N33/564 ,  G01N33/6863 ,  G01N33/6893 ,  G01N2333/415 ,  G01N2333/521 ,  G01N2333/522 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/06 ,  G01N2800/50

Abstract: Provided herein compositions comprising gluten and methods of use thereof. In some aspects, compositions comprising ratios of wheat flour protein, rye flour protein, and barley flour protein are provided and methods of use thereof.

Abstract translation: 包含面筋的组合物及其使用方法。 在一些方面，提供了包含小麦粉蛋白质，黑麦粉蛋白质和大麦粉蛋白质的比例的组合物及其使用方法。

公开(公告)号：WO2015021166A3

公开(公告)日：2015-05-07

申请号：PCT/US2014049957

申请日：2014-08-06

Applicant: ALEXION PHARMA INC

Inventor： MCKNIGHT SUSAN FAAS ,  COFIELL ROXANNE ,  KUKREJA ANJLI ,  YAN YAN ,  BEDARD KRYSTIN A

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/76 ,  G01N33/6863 ,  G01N2333/4716 ,  G01N2333/485 ,  G01N2333/522 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/5434 ,  G01N2333/545 ,  G01N2333/57 ,  G01N2333/70503 ,  G01N2333/70525 ,  G01N2333/70539 ,  G01N2333/7151 ,  G01N2333/7452 ,  G01N2333/75 ,  G01N2333/775 ,  G01N2333/8139 ,  G01N2333/8146 ,  G01N2333/974 ,  G01N2800/226 ,  G01N2800/347 ,  G01N2800/50 ,  G01N2800/52

Abstract: The disclosure provides biomarker proteins, a change in the concentration or activity level of which are associated with atypical hemolytic uremic syndrome (aHUS) or clinically meaningful treatment of aHUS with a complement inhibitor. Also provided are compositions and methods for interrogating the concentration and/or activity of one or more of the biomarker proteins in a biological fluid. The compositions and methods are useful for, among other things, evaluating risk for developing aHUS, diagnosing aHUS, determining whether a subject is experiencing the first acute presentation of aHUS, monitoring progression or abatement of aHUS, and/or monitoring response to treatment with a complement inhibitor or optimizing such treatment.

Abstract translation: 本公开提供了生物标志物蛋白质，其浓度或活性水平的变化与非典型溶血性尿毒症综合征（aHUS）相关，或临床意义上用补体抑制剂治疗HUS。 还提供了用于询问生物流体中一种或多种生物标记蛋白的浓度和/或活性的组合物和方法。 组合物和方法可用于评估发展为高血压的风险，诊断高血压，确定受试者是否正在经历第一次急性呈现的HUS，监测进展或减轻HUS，和/或监测对治疗的反应 补体抑制剂或优化这种治疗。

公开(公告)号：WO2015042602A1

公开(公告)日：2015-03-26

申请号：PCT/US2014/057049

申请日：2014-09-23

Applicant: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION ,  CHAVES FONTES, Paulo, A. ,  KELLUM, John, A.

Inventor： CHAVES FONTES, Paulo, A. ,  KELLUM, John, A.

IPC: C12Q1/68

CPC classification number: G01N33/6863 ,  C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2333/525 ,  G01N2333/5406 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/5428 ,  G01N2333/5434 ,  G01N2333/545 ,  G01N2333/56 ,  G01N2333/57 ,  G01N2570/00 ,  G01N2800/085 ,  G01N2800/50 ,  G01N2800/60

Abstract: Disclosed herein are methods of identifying biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) that can be used to predict organ or tissue function or dysfunction. In some embodiments, the methods include ex vivo perfusion of the organ or tissue, collection of samples from the organ or tissue (for example, perfusate, fluids produced by the organ (such as bile or urine), or tissue biopsies) and measuring the level of one or more biomarkers in the sample. It is also disclosed herein that an analysis of biomarkers (such as genes (e.g., RNA or mRNA), proteins, and/or small molecules) present in a biological sample from an organ, tissue, or subject can be used to identify whether the organ, tissue, or subject is at risk for (or has) organ dysfunction or organ failure.

Abstract translation: 本文公开了可用于预测器官或组织功能或功能障碍的生物标志物（例如基因（例如RNA或mRNA），蛋白质和/或小分子）的方法。 在一些实施方案中，所述方法包括器官或组织的离体灌注，来自器官或组织（例如，灌注液，由器官（如胆汁或尿液）产生的流体）或组织活组织检查）的样品的收集，并测量 样品中一种或多种生物标志物的水平。 本文还公开了可以使用存在于来自器官，组织或受试者的生物样品中的生物标志物（例如RNA或mRNA），蛋白质和/或小分子的分析来鉴定是否 器官，组织或受试者处于（或具有）器官功能障碍或器官衰竭的风险中。

公开(公告)号：WO2015038624A1

公开(公告)日：2015-03-19

申请号：PCT/US2014/054959

申请日：2014-09-10

Applicant: IMMUSANT, INC.

Inventor： ANDERSON, Robert, P.

IPC: A61K38/10 ,  A61P1/00

CPC classification number: A61K38/10 ,  A61K9/0021 ,  A61K9/08 ,  G01N33/6866 ,  G01N2333/55 ,  G01N2333/57

Abstract: Provided herein are methods and compositions for treating subjects with Celiac disease.

Abstract translation: 本文提供用于治疗患有乳糜泻病的受试者的方法和组合物。

公开(公告)号：WO2014194053A2

公开(公告)日：2014-12-04

申请号：PCT/US2014039963

申请日：2014-05-29

Applicant: SIAMAB THERAPEUTICS INC

Inventor： ZHANG MAI ,  GHADERI DARIUS ,  BEHRENS JEFFREY ,  HERMANN JULIE

IPC: A61K38/17 ,  A61K31/726

CPC classification number: A61K38/018 ,  A23L13/42 ,  A23L15/30 ,  A23L33/10 ,  A23L33/18 ,  A23L33/19 ,  A23L33/30 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/7012 ,  A61K35/20 ,  A61K35/57 ,  A61K45/06 ,  G01N33/5308 ,  G01N33/6863 ,  G01N2333/523 ,  G01N2333/525 ,  G01N2333/5409 ,  G01N2333/5412 ,  G01N2333/57 ,  G01N2800/52 ,  G01N2800/7095 ,  A61K2300/00

Abstract: Embodiments of the present invention provide compositions and methods for the modulation of sialic acid levels. In some embodiments, compositions disclosed herein comprise nutraceuticals as functional agents.

Abstract translation: 本发明的实施方案提供了调节唾液酸水平的组合物和方法。 在一些实施方案中，本文公开的组合物包含作为功能剂的营养药物。

公开(公告)号：WO2014173463A1

公开(公告)日：2014-10-30

申请号：PCT/EP2013/058787

申请日：2013-04-26

Applicant: SYNTHON BV

Inventor： WEIJTS, Francisca Antoinette Adriana ,  KOLEN, Sebastianus Martinus Henricus

IPC: G01N33/68 ,  G01N33/50

CPC classification number: G01N33/5011 ,  G01N33/5023 ,  G01N33/5047 ,  G01N33/505 ,  G01N33/6863 ,  G01N2333/57 ,  G01N2333/7155 ,  G01N2800/285

Abstract: The present invention relates to a method to determine the potency of a batch of glatiramer acetate comprising stimulating human monocytic cell line cells with an effective amount of interferon gamma (IFNγ), exposing said cells to said batch of glatiramer acetate, and determining the expression of the monocyte anti-inflammatory cytokine s IL-1Ra or the inhibition of proliferation of said cells induced by glatiramer acetate.

Abstract translation: 本发明涉及一种确定一批醋酸格拉默的效力的方法，包括用有效量的干扰素γ（IFNγ）刺激人单核细胞系细胞，将所述细胞暴露于所述批次的醋酸格拉默，并确定 单核细胞抗炎细胞因子IL-1Ra或由醋酸格拉默诱导的所述细胞的增殖的抑制。